Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Stefano Cascinu(Vita-Salute San Raffaele University), Emiliano Tamburini(Ospedale Infermi di Rimini), Margherita Rimini(Vita-Salute San Raffaele University), Naoya Sakamoto(Chibaken Saiseikai Narashino Hospital), Goki Suda(Sapporo University), Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Hidenori Toyoda(Ogaki Municipal Hospital), André Jefremow(Universitätsklinikum Erlangen), Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Masatoshi Kudo(Kindai University), Mario Scartozzi(University of Cagliari), Wonseok Kang(Samsung Medical Center), Shigeo Shimose(Kurume University), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Takashi Kumada(Gifu Kyoritsu University), Myung Ji Goh(Samsung Medical Center), Valentina Burgio(Vita-Salute San Raffaele University), Claudia Campani(Inserm), Ei Itobayashi(Asahi General Hospital), Takuya Sho(Hokkaido University), Toshifumi Tada(Himeji Red Cross Hospital), Kazuomi Ueshima(Kindai University), Masanori Atsukawa(Nippon Medical School), Tomoko Aoki(Kindai University Hospital), Hideki Iwamoto, Takuji Torimura(Omuta hospital), Jürgen Siebler(Universität Hamburg), Francesco Tovoli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 43
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k